Test detects signs of urothelial cancer using urine test

Nov. 12, 2021

Researchers have shown that it is possible to detect signs of urothelial cancer using a simple urine test in Lynch Syndrome patients who are at high risk of developing tumors.

The findings by Newcastle University experts, presented at the NCRI Festival, offer the potential to develop a cheap, easy, and non-invasive way of screening Lynch Syndrome (LS) patients for cancers of the bladder, kidney and ureter.

LS is an inherited genetic disorder that carries a high risk of cancer. Patients with LS are at high risk of bowel and endometrial cancers. The risk of urothelial cancer is less well recognized, with a lifetime risk of up to 28.5%, depending on which gene is involved.

Failure to screen for these cancers means that even after being diagnosed with the condition, one in 20 LS patients will die of urothelial cancer, often at a young age.

This has recently become the standard test in North East England to find people with LS among those diagnosed with bowel cancer. MSI, which stands for microsatellite instability, shows that an important DNA repair system isn’t working. Most LS patients are in this group. The test is being evaluated for national rollout.

To see if the test could be used for urothelial cancers as well as bowel cancer, the researchers tested blood and urine samples in a LS patient who had been diagnosed with urothelial cancer in the upper urinary tract. They tested the urine before and after surgery to remove the tumor.

The researchers are setting up a regional pilot study in which they will collect urine samples from LS patients between the ages of 40 and 75 who have a confirmed diagnosis of LS based on DNA testing their blood, either after they present with cancer or because they have an affected relative. Initially, the researchers will target patients with LS that is caused by a mutation in the MSH2 gene, as this is the group of patients with the greatest risk of cancer.

This means that those LS patients who have an underlying defect in the MSH2 gene are more than 10 times as likely to get a potentially curable cancer in their urinary tract than the general population.

Visit Newcastle University for more news